Results 11 to 20 of about 644,115 (313)

Direct factor Xa inhibitors and the risk of cancer and cancer mortality: A Danish population-based cohort study. [PDF]

PLoS Medicine
BackgroundPreclinical animal studies have suggested that myeloid cell-synthesized coagulation factor X dampens antitumor immunity and that rivaroxaban, a direct factor Xa inhibitor, can be used to promote tumor immunity. This study was aimed at assessing
Floris Bosch, Erzsébet Horváth-Puhó, Suzanne C Cannegieter, Nick van Es, Henrik T Sørensen   +4 more
doaj   +2 more sources

Monitoring anti-factor Xa activity in patients with chronic thromboembolic pulmonary hypertension treated with factor Xa inhibitors [PDF]

Scientific Reports
Direct oral anticoagulants (DOACs) have been used clinically in patients with chronic thromboembolic pulmonary hypertension (CTEPH) for secondary prevention after acute venous thromboembolism, although the data are limited.
Yoshihisa Nakano, Shiro Adachi, Miku Hirose, Takeshi Adachi, Itsumure Nishiyama, Kenichiro Yasuda, Masahiro Yoshida, Takahisa Kondo, Toyoaki Murohara   +8 more
doaj   +2 more sources

Application of Molecular Modeling to Development of New Factor Xa Inhibitors [PDF]

BioMed Research International, 2015
In consequence of the key role of factor Xa in the clotting cascade and absence of its activity in the processes that do not affect coagulation, this protein is an attractive target for development of new blood coagulation inhibitors.
Alexey V. Sulimov, Danil C. Kutov, Ekaterina V. Katkova, Elena I. Sinauridze, Fazoil I. Ataullakhanov, Irina V. Gribkova, Khidmet S. Shikhaliev, Maria P. Kochugaeva, Michael Yu. Krysin, Svetlana M. Medvedeva, Vladimir B. Sulimov   +10 more
core   +4 more sources

Pharmacodynamics and Pharmacokinetics of oral factor Xa inhibitors

Clinical Pharmacology: Advances and Applications, 2015
Pontus B Persson Institute of Vegetative Physiology, Berlin, GermanyApixaban and rivaroxaban are oral factor Xa inhibitors. In a recent issue of Clinical Pharmacology: Advances and Applications, Frost et al compare apixaban (2.5 mg, twice daily) to ...
Persson PB
doaj   +5 more sources

Reversal of Factor Xa Inhibitors by Andexanet Alfa May Increase Thrombogenesis Compared to Pretreatment Values

Clinical and Applied Thrombosis/Hemostasis, 2019
Recombinant coagulation factor Xa (FXa), inactivated Zh-zo, also known as andexanet alfa (AA), is a modified version of human FXa that has been developed to neutralize FXa inhibitors.
Fakiha Siddiqui BDS, Alfonso Tafur MD, Lorenzo Storino Ramacciotti BS, Walter Jeske PhD, Debra Hoppensteadt PhD, Eduardo Ramacciotti MD, PhD, Omer Iqbal MD, FACC, FESC, Jawed Fareed PhD   +7 more
doaj   +2 more sources

Effect of PCC on Thrombin Generation among Patients on Factor Xa Inhibitors with Major Bleeding or Needing Urgent Surgery (GAUGE): Design and Rationale [PDF]

TH Open, 2023
Background Direct factor Xa inhibitors (FXaIs) account for most oral anticoagulant use and FXaI-associated bleeding events are common. Clinicians have variable national and regional access to specific FXaI reversal agents such as andexanet ...
Shaw Shaw, Unachukwu Unachukwu, Cyr Cyr, Siegal Siegal, Castellucci Castellucci, Dreden Dreden, Dowlatshahi Dowlatshahi, Buyukdere Buyukdere, Ramsay Ramsay, Carrier Carrier   +9 more
doaj   +2 more sources

Factor Xa Inhibitors Versus Vitamin K Antagonists in Atrial Fibrillation Patients with End-Stage Kidney Disease on Dialysis: A Meta-Analysis [PDF]

Clinical and Applied Thrombosis/Hemostasis
Background Atrial fibrillation (AF) is prevalent among patients with end-stage kidney disease (ESKD) undergoing dialysis, and both conditions are associated with a heightened risk of cardiovascular diseases.
Meimei Xiong MS, Linjuan Guo MD, Yun Wan MS   +2 more
doaj   +2 more sources

Andexanet alfa for the reversal of factor Xa inhibitors

Expert Opinion on Biological Therapy, 2019
Andexanet alfa is a recombinant modified factor Xa protein that has been developed to reverse factor Xa inhibitors. Since May 2018, the FDA has approved its utilization in patients treated with apixaban and rivaroxaban in case of life-threatening or uncontrolled bleeding.
J Favresse, M Hardy, MA van Dievoet, AL Sennesael, J Douxfils, CM Samama, O Vornicu, AS Dincq, S Lessire, F Mullier   +9 more
openaire   +5 more sources

Clinical Pathways and Outcomes of Andexanet Alfa Administration for the Reversal of Critical Bleeding in Patients on Oral Direct Factor Xa Inhibitors [PDF]

TH Open
Background Andexanet is U.S. Food and Drug Administration (FDA) approved for the reversal of critical bleeding from factor Xa inhibitors and off-label for surgical reversal. Data are lacking on andexanet administration processes.
Mark Goldin, Kolton Smith, Ioannis Koulas, Tungming Leung, Mayuri Ravi, Sanjit Parhar, Sejal Shah, Kayla Floyd, Lori Ohanesian, Rachel Bain, Daniella Defonte, Kanta Ochani, Amanda Lin, Bhumi Patel, Nikolaos Tsaftaridis, Jack Jnani, Alex C. Spyropoulos   +16 more
doaj   +2 more sources

Fondaparinux sodium: A selective inhibitor of factor Xa

American Journal of Health-System Pharmacy, 2001
The pharmacology and mechanism of action of fondaparinux sodium are described. Fondaparinux sodium is the first agent of a new class of anticoagulants that selectively target factor Xa. It has a linear, dose-dependent pharmacokinetic profile, which provides a highly predictable response.
Kenneth A. Bauer
openalex   +4 more sources